Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) partnered with Nanjing Vazyme Biotech (SHA:688105) in a cooperation agreement to set up a biopharmaceutical joint venture, according to a Shanghai bourse filing on Saturday.
The venture will set up production lines that will produce 10 tons of active pharmaceutical ingredients every year.
Sinopep-Allsino will own 51% of the venture, and Vazyme Biotech will hold 49%.
Sinopep-Allsino's shares closed 10% higher, while Vazyme Biotech's shares closed over 5% higher.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。